The clinical, cardiovascular and neuroendocrine profile of ampreloxetine showed target engagement of residual peripheral autonomic neurons and a sustained standing blood pressure effect, which is ...

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be ...

YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of $854M, as reported by GSK, increased ...

†High patient compliance after training. ‡Likely to be preferred for frail patients. Adapted from [34].

These analyses support the Company's understanding of ampreloxetine's highly selective mechanism of action and potential to address symptoms of neurogenic orthostatic hypotension (nOH) in patients ...

Orthostatic hypotension (OH) is a common disorder in older adults. The pathophysiology of OH in older adults occurs commonly as a consequence of decreased effective circulating volume and/or ...

ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.

It is the end effect of multiple pathologies - neural, orthostatic hypotension, cardiac, all of which have a peculiar origin - an evolutionary bane. Humans adopted the upright posture to enable ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity ...

Nearly 13,000 Virginians received just under 2.3 million meals through Meals on Wheels in 2024, according to the Virginia ...